Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088933 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00088933: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00088933 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088933, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
This randomized phase I trial studies the side effects, best way to give, and best dose of docetaxel when given together with vaccine therapy and sargramostim in treating patients with metastatic lung cancer or metastatic colorectal cancer. Vaccines may make the body build an immune response to kill tumor cells. Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow and peripheral blood. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining vaccine therapy and sargramostim with docetaxel may kill more tumor cells.
Interventions
- DRUG docetaxel
- DRUG sargramostim
- DRUG recombinant fowlpox-CEA(6D)/TRICOM vaccine
- DRUG recombinant vaccinia-CEA(6D)-TRICOM vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2004-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00088933
The ClinicalTrials.gov registry entry for NCT00088933 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which docetaxel is the first listed.
NCT00088933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00088933 about?
NCT00088933 is a clinical study titled "Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer". This randomized phase I trial studies the side effects, best way to give, and best dose of docetaxel when given together with vaccine therapy and sargramostim in treating patients with metastatic lung cancer or metastatic colorectal cancer. Vaccines may make the body build an immune response to kill...
What is the current status of trial NCT00088933?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2004-06.
What interventions are being tested in trial NCT00088933?
The interventions under investigation include: docetaxel (DRUG), sargramostim (DRUG), recombinant fowlpox-CEA(6D)/TRICOM vaccine (DRUG), recombinant vaccinia-CEA(6D)-TRICOM vaccine (DRUG).
Who is sponsoring clinical trial NCT00088933?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.